Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib plus fulvestrant: Results from MONALEESA-3 (2018) Fasching P, Esteva FJ, Pivot X, Nusch A, Beck JT, Chan A, Pieris-Gunatilaka A, et al. Conference contribution Phase I dose-escalation and expansion study of intratumoral CV8102, a RNA-based TLR- nd RIG-1 agonist in patients with advanced solid tumors (2018) Terheyden P, Weishaupt C, Heinzerling L, Klinkhardt U, Krauss J, Mohr P, Kiecker F, et al. Conference contribution Cetuximab in combination with platinum-based chemotherapy or radiotherapy in patients with recurrent and/or metastatic SSCHN in clinical routine: Updated interim results of the prospective SOCCER study (2018) Hecht M, Hahn D, Wolber P, Hautmann M, Reichert D, Weniger J, Belka C, et al. Conference contribution COMPETE trial: Peptide receptor radionuclide therapy (PRRT) with 177Lu-edotreotide vs. everolimus in progressive GEP-NET (2018) Pavel ME, Rinke A, Baum RP Conference contribution A prediction model for pathological complete response after neoadjuvant chemotherapy of HER2-negative breast cancer patients (2018) Häberle L, Erber R, Gaß P, Hein A, Jud S, Langemann H, Rauh C, et al. Conference contribution Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients (2018) Roellig C, Kramer M, Gabrecht M, Haenel MH, Herbst R, Kaiser U, Schmitz N, et al. Journal article Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients (2018) Nabieva N, Kellner S, Fehm T, Häberle L, De Waal J, Rezai M, Baier B, et al. Journal article Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial (2018) Ignatiadis M, Litiere S, Rothe F, Riethdorf S, Proudhon C, Fehma T, Aalders K, et al. Journal article Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto (2018) Loibl S, Weber KE, Timms KM, Elkin EP, Hahnen E, Fasching P, Lederer B, et al. Journal article Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trial (2018) Hofheinz RD, Arnold D, Fokas E, Kaufmann M, Hothorn T, Folprecht G, Fietkau R, et al. Journal article